Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08CA069164-01A1
Application #
2009110
Study Section
Cancer Research Manpower and Education Review Committee (CRME)
Project Start
1996-09-17
Project End
2001-08-31
Budget Start
1996-09-17
Budget End
1997-08-31
Support Year
1
Fiscal Year
1996
Total Cost
Indirect Cost

  Institution

Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218

  Publications

Verheul, Henk M W; Qian, David Z; Carducci, Michael A et al. (2007) Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs. Cancer Chemother Pharmacol 60:329-39
Nelson, Joel B; Nabulsi, Azmi A; Vogelzang, Nicholas J et al. (2003) Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan. J Urol 169:1143-9
Carducci, M A; Gilbert, J; Bowling, M K et al. (2001) A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res 7:3047-55
Pili, R; Kruszewski, M P; Hager, B W et al. (2001) Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 61:1477-85